NaV1.7 Targeting Antisense Oligonucleotides: Emerging Modalities for Pain & Pipeline Development
11:00 am - Thursday 24th September 2026
- Utilizing ASOs as a novel way to modulate NaV1.7, which can circumvent the existing issues with small molecule inhibitors (e.g. autonomic side effects)
- Exploring how Quiver’s integrated platform based on all-optical electrophysiology and machine learning has led to identifying novel candidate molecules alongside therapeutic targets
- Demonstrating how Quiver’s platform can enrich the genetic medicine drug candidates with maximized therapeutic index